SCHEMBL3246229

SCHEMBL3246229

COc1ccc(S(=O)(=O)NCC(=O)N(C)c2ccc(Cl)cc2N(C)c2ccccc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 3/20 0.49
HCRTR1 O43613 2/20 0.49
PKM P14618 2/20 0.47
MAPK1 P28482 1/20 0.46
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
ALDH1A1 P00352 5/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 3/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257032 0.84 MAPK1 (0.48) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL4867340 0.84 TSHR (0.51) PKMMAPK1FLT1FLT4KDR
SCHEMBL3247585 0.83 MAPK1 (0.44) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL3263100 0.82 MAPK1 (0.57) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL4867766 0.80 MAPK1 (0.48) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL3256844 0.80 MAPK1 (0.48) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL4863796 0.80 MAPK1 (0.48) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL4870949 0.80 MAPK1 (0.49) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL3250435 0.79 MAPT (0.44) HCRTR2HCRTR1PKMMAPK1FLT1
SCHEMBL3256243 0.78 ALDH1A1 (0.63) PKMMAPK1FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 HCRTR2 1/4885HCRTR1 6/4885PKM 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.